Kinases inhibitors in lung cancer: From benchside to bedside

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Conventional chemotherapy has limitations including toxicity and lack of selectivity.
• Kinases remain highly effective molecular targets for lung cancer therapy.

Purpose of the Study:

• To review chemical scaffolds used as lung cancer inhibitors.
• To explain the design rationale and target interactions of these inhibitors.
• To present biological data and potential challenges of current inhibitors.

Main Methods:

• Literature review of approved and investigational lung cancer inhibitors.
• Analysis of chemical scaffolds and their design principles.
• Evaluation of biological data and clinical relevance.

Main Results:

• Irreversible kinase inhibitors form covalent bonds, offering prolonged pharmacodynamics and high potency.
• Various chemical scaffolds are utilized, with afatinib as an example of approved irreversible inhibitors.
• Detailed insights into inhibitor design, target interactions, and biological activity are presented.

Conclusions:

• Irreversible kinase inhibitors represent a significant advancement in lung cancer treatment.
• Understanding inhibitor design and interactions is key to developing more effective therapies.
• Further research into chemical scaffolds and their challenges will refine lung cancer treatment strategies.